The treatment of this potentially fatal complication is not universally accepted. Early exchange transfusion seems to be the most accepted and effective form of therapy. The aim of this therapy is to reduce and maintain the haemoglobin S level at less than 30%. Clinical improvement may result from the exchange transfusion of RBC or FFP or both [9].

References

Uncommon presentation of hypereosinophilic syndrome
J Rajkanna¹, J Indrakumar², S Kamaladasa², C C Kariyawasan³

(Index words: hypereosinophilic syndrome, mucosal ulceration)

Introduction
The hypereosinophilic syndrome is a group of diseases characterised by persistent blood eosinophilia, defined as more than 1500 cells per micro liter [1], with end-organ involvement and no recognised secondary causes such as skin diseases, parasitic infection or allergy (Table). The sustained overproduction of eosinophils causes eosinophilic infiltration and release of mediators causing damage to multiple organs [2]. Cutaneous involvement occurs in more than 50% of patients, but it usually appears late in the disease and is of less importance than cardiac and other organ involvement [1]. We describe a patient with the hypereosinophilic syndrome (HES) in whom the initial manifestation of the disease was recurrent, severe mucosal ulcers involving the mouth and genitalia.

Case report
A 39-year old man was well until January 2007 when he developed persistent oral ulcers. Two months later, the oral ulcers increased and he also developed erosive lesions on the glans penis and ulceration of the skin of the scrotum (Figures 1 and 2). Clinical examination of the heart, lungs and abdomen were unremarkable and there were no other skin lesions. His white cell count was 35×10⁹/l with 54% eosinophils. He underwent investigations including stool tests for amoebae, ova and cysts, and bone marrow examination which did not show a cause for his illness. He was treated with sequential courses of intravenous antibiotics, albendazole, di-ethyl carbamazine and a short course of steroids without improvement in his symptoms or eosinophil count. He was discharged from hospital and was followed up in the clinic.

In August 2007 he was re-evaluated because of persistent orogenital ulcers and eosinophilia without other skin lesions. His white blood counts at that time were 23×10⁹/l with 60% eosinophils. The haemoglobin and platelets were within normal range. Eosinophilic leukaemia (myeloid cells that demonstrate a clonal chromosomal abnormality [4]) was excluded by blood picture, bone

¹University Medical Unit, Colombo South Teaching Hospital, Kalubowila, and Departments of ²Medicine and ³Pathology, Faculty of Medical Sciences, University of Sri Jayawardenepura, Nugegoda, Sri Lanka.
Correspondence: JI, e-mail <sathika@stnet.lk>. Received 29 December 2008 and revised version accepted 16 May 2009. Competing interest: none declared.
marrow, normal NAP (neutrophil alkaline phosphatase) score and negative BCR-ABL gene (RT-PDR) studies. Multiple skin and mucosal biopsies excluded pemphigus and other skin diseases. The pathergy test, CEA, ANF, PSA, VDRL, skin smears and antibodies for herpes simplex were negative. Ultrasound scan of the abdomen showed mild splenomegaly. 2D echo cardiogram showed normal cardiac structure and function.

**Discussion**

The hypereosinophilic syndrome is a multisystem disease characterised by infiltration of eosinophils in the bone marrow, heart, and other organs [2]. Cutaneous, and rarely, mucosal involvement occurs, but unlike in our patient they usually appear late in the disease [2]. Mucosal ulcerations can cause significant morbidity and are difficult to treat.

Mucosal ulcerations are a variant presentation that appear to be a marker for a mutation that characterises a subgroup of HES patients [3]. A proportion of HES patients have a mutation involving the PDGFRA and FIP1L1 genes on the fourth chromosome, leading to a tyrosine kinase fusion protein. The prevalence of the FIP1L1-PDGFRA alpha fusion gene in patients with HES is reported to be 11% [3]. Its presence indicates responsiveness to imatinib, a tyrosine kinase inhibitor [1].

**Table. Diagnostic criteria for hypereosinophilic syndrome**[2]

<table>
<thead>
<tr>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Eosinophil counts &gt;1.5×10⁹/l for &lt;6 months or &lt;6 months with evidence of organ damage</td>
</tr>
<tr>
<td>2. Lack of evidence for parasitic, allergic, or other recognised causes of eosinophilia</td>
</tr>
<tr>
<td>3. Symptoms and signs of organ-system involvement</td>
</tr>
</tbody>
</table>

**References**


